Agios
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Agios and other ETFs, options, and stocks.About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology.
AGIO Key Statistics
AGIO News
Investors in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) had a good week, as its shares rose 9.7% to close at US$34.54 following the release of its first-quarter...
Agios Pharmaceuticals AGIO reported a loss of $1.45 per share in first-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of $1.64. In the year-...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks amon...
Analyst ratings
67%
of 9 ratingsMore AGIO News
Agios Pharmaceuticals (NASDAQ:AGIO) First Quarter 2024 Results Key Financial Results Revenue: US$8.19m (up 46% from 1Q 2023). Net loss: US$81.5m (flat on 1Q...
Participants Christopher Taylor; Vice President, Investor Relations and Corporate Communications; Agios Pharmaceuticals Inc Brian Goff; Executive Vice Preside...
Revenue: Reported Q1 2024 net product revenue of $8.2 million from PYRUKYND, up from $5.6 million in Q1 2023, slightly below the estimated $8.37 million. Net L...
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of...
Agios expects to execute on the following additional key milestones and priorities by the end of 2024: Thalassemia: Two key milestones for the year, including r...
Reports Q1 revenue $8.2M, consensus $8.37M. “We were delighted to report positive data from the Phase 3 ENERGIZE study of mitapivat in non-transfusion-dependent...